"A total of 154 atherosclerotic events occurred: 68 in the aspirin group and 86 in the nonaspirin group. In the 1,363 patients aged 65 years or older (719 in the aspirin group and 644 in the nonaspirin group), the incidence of atherosclerotic events was significantly lower in the aspirin group (45 events, 6.3 percent) than in the nonaspirin group (59 events, 9.2 percent)," the researchers said.
In the 1,176 patients younger than 65 the difference among events in the two groups was not significant.
Aspirin was well tolerated: in comparing bleeding events, the researchers reported 13 hemorrhagic strokes, with no statistically significant difference
between aspirin takers and non-takers (six such strokes in the aspirin group; seven in the non-aspirin group).
There was a comparable number of the combined endpoint of serious hemorrhagic events (hemorrhagic strokes and major gastrointestinal bleeds).
While this study did not find that low-dose aspirin significantly reduced the risk of atherosclerotic events in primary prevention therapy in patients with type 2 diabetes, the authors suggest more research is needed.
The study will appear in the November 12 print issue of JAMA.
Source-ANI
SPH